Andrius Baskys, MD
Psychiatry · Riverside, CANPI 1124110069
Payments from drug & device makers
What this record shows
This record is dominated by food and beverage: $216 of the $313 with a category attached, or 69.0%. It is spread thinly across 9 manufacturers, the largest accounting for just 23.8%. 2024 is the largest year on record at $124, 2.0 times the $60 reported in 2019.
Across 10 payments — averaging $31.31 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- Boehringer Ingelheim$74
- Amgen$64
- AbbVie$49
- Johnson & Johnson$48
- Novo Nordisk$20
- GSK$17
- plus $40 from 3 others
What the payments were for
- Food & beverage$21669%
- Education$9731%
Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| Boehringer Ingelheim | 1 | $74 |
| Amgen | 2 | $64 |
| AbbVie | 1 | $49 |
| Johnson & Johnson | 1 | $48 |
| Novo Nordisk | 1 | $20 |
| GSK | 1 | $17 |
| Genentech USA, Inc. | 1 | $16 |
| Dexcom, Inc. | 1 | $13 |
| Sunovion Pharmaceuticals Inc. | 1 | $11 |
How this compares
$313 in reported general payments places this provider in the 60th percentile of 4,954 psychiatry providers in California.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| Abilify MaintenaAripiprazole | 17 | $47,067 |
| Clozapine | 11 | $937 |
| Olanzapine | 79 | $823 |
| Quetiapine Fumarate | 62 | $681 |
| Venlafaxine Hcl ErVenlafaxine Hcl | 46 | $630 |
| Sertraline Hcl | 76 | $511 |
| Haloperidol | 11 | $474 |
| Duloxetine Hcl | 33 | $417 |
| Risperidone | 38 | $414 |
| Mirtazapine | 28 | $406 |
| Lorazepam | 57 | $374 |
| Buspirone Hcl | 28 | $335 |
| Chlordiazepoxide Hcl | 11 | $198 |
| Bupropion Hcl SrBupropion Hcl | 23 | $192 |
| Zolpidem Tartrate | 17 | $184 |
Paid to pharmacies, not to this prescriber.
Other psychiatry in Riverside
- Ramesh PatelRiverside$112K
- Deepak RajpootRiverside$109K
- Gustavo AlvaOrange$5.8M
- John KooSan Francisco$3M
- Jason KelloggIrvine$2.7M
- Jonathan MeyerSan Diego$2.3M
- Charles Tuan-Tu NguyenIrvine$2.1M
- Manoj WaikarLos Gatos$1.9M
- Gerald MaguireSan Juan Capistraco$1.8M
- Salima BrillmanSunnyvale$1.4M
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.